BRIDGING PRECLINICAL AND CLINICAL RESEARCH FOR GYNECOLOGICAL CANCERS
GYNE PDX
platforM
gynE pdx platform
Bridging preclinical and clinical research for gynecological cancers
The GYNE PDX platform includes patient-derived xenograft models and its derived organoids (PDXOs) of endometrial and ovarian cancers, and is available for use at all stages of cancer drug discovery. We have the capacity to expand our know-how to other GYNecological cancers upon request. Importantly, our PDX and PDXO models are accompanied by molecular and clinical data, enabling the correlation of therapeutic response with specific molecular features for a personalized medicine approach.
Thanks to the GYNE PDX Platform, we aim to help pharma companies, biotechs and academic groups to streamlining drug development towards specific patient populations and indications for investigational agents;
bridging the gap between preclinical and clinical research for gynecological cancers.
gynE
PDX & PDXO biobank
We develop Patient-derived Xenograft (PDX) models by transplanting differentiated areas of a patient's tumor into mice, permitting to accurately reproduce the human intra-tumor and intra-patient heterogeneity in a murine model.
Patient-derived Xenograft Organoids (PDXO) are developed from PDX tumor tissues and used for drug screenings in vitro.
The GYNE PDX Platform currently has 164 PDX and PDXO models available representing more than 90 gynecological cancer patients (mainly endometrial cancer).
team
Our team is the Group of Biomedical Research in Gynecology, in Vall d’Hebron Institute of Research, Barcelona, Spain. We are an academic multidisciplinary team made up of clinical specialists in gynecology and pathology and translational researchers. Our research is clearly translational.
We are seeking partners among drug developers to advance on adequating the best treatment for each gynecological cancer patient.
Our team is experienced to plan / guide the study design, execute the preclinical studies, and conduct data analysis and interpretation. We know the disease that we are working on, and we have proven track record on conducting preclinical studies with pharma companies, biotechs and academic groups.
